InspireMD (NSPR) Q1 2025 earnings summary

Executive summary

• CGuard revenue for Q1 2025 was $1.53 million, up 1.2% year-over-year, with 2,611 stents sold internationally and ongoing expansion into the U.S. market supported by positive clinical trial results.

• Anticipated U.S. FDA approval for CGuard Prime is expected in Q3 2025, with commercial launch preparations and sales force expansion underway.

• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and insufficient resources to fund operations for the next 12 months.

• Clinical pipeline progress includes strong enrollment in pivotal studies and new feasibility studies for acute stroke applications.

Financial highlights

• Q1 2025 revenue increased 1.2% to $1,529,000, with gross profit flat at $292,000 and gross margin at 19.1%.

• Operating expenses rose 52.5% year-over-year to $11,752,000, mainly due to U.S. sales force expansion and launch preparations.

• Net loss widened to $11,166,000 ($0.22 per share) from $7,032,000 ($0.21 per share) in Q1 2024, driven by higher R&D, selling, and G&A expenses.

• Cash and equivalents were $26,086,000 as of March 31, 2025, down from $34,637,000 at year-end 2024.

• Operating cash outflow rose 73.6% year-over-year to $8,790,000, mainly due to increased compensation and third-party expenses.

Outlook and guidance

• Confident in achieving FDA approval for CGuard Prime in Q3 2025, with robust commercial launch plans and management focused on execution.

• U.S. launch expected to drive significant revenue growth, leveraging a strong sales team and domestic production.

• Anticipates first half 2026 FDA approval for CGuard Prime in TCAR procedures and late 2026 clearance for SwitchGuard neuroprotection system.

• Management plans to seek additional capital through equity, debt, or partnerships, but there is no assurance of success.

• Additional financing tranches tied to regulatory milestones could raise up to $113.6 million.